

## Acneiform Eruptions

[View the current Acneiform Eruptions InDepth page on BioPortfolio.com \(PDF\)](#)  
([http://www.bioportfolio.com/indepth/Acneiform\\_Eruptions.html](http://www.bioportfolio.com/indepth/Acneiform_Eruptions.html)) - Regularly Updated.



### Recent Publications on Acneiform Eruptions:

- [Subcision in rolling acne scars with 24G needle.](#)  
*The epidermal growth factor receptor (EGFR) inhibitor erlotinib was found...*17th November, 2009  
- Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):677-9.
- [A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.](#)  
*BACKGROUND: Clinical trials addressing the acneiform rash associated with...*9th October, 2009  
Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New- J Am Acad Dermatol. 2009 Oct;61(4):614-20. Epub 2009 Jul 31. ([DOI Direct Link](#))
- [Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.](#)  
*The epidermal growth factor receptor (EGFR) inhibitor cetuximab is used to...*3rd October, 2009  
- Eur J Dermatol. 2009 Oct 2. ([DOI Direct Link](#))
- [Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate.](#)  
*Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome...*25th September, 2009  
Department of Dermatology, Boston University School of Medicine, Boston,- J Am Acad Dermatol. 2009 Jul;61(1):123-5. ([DOI Direct Link](#))
- [Erlotinib-induced pustular eruption.](#)  
*The epidermal growth factor receptor (EGFR) inhibitor erlotinib was found...*15th August, 2009  
Unit of Dermatology, G. Rummo Hospital, Benevento, Italy.- G Ital Dermatol Venereol. 2009 Feb;144(1):93-6.
- [Facial acneiform rash associated with sorafenib.](#)  
*Sorafenib is an oral multikinase inhibitor that is useful in the treatment...*7th August, 2009  
Dermatology Department, Ramon y Cajal Hospital, University of Alcalá de- Dermatol Online J. 2009 Apr 15;15(4):7.
- [Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.](#)  
*Erlotinib and cetuximab are human epidermal growth factor receptor...*25th July, 2009  
Servico de Dermatologia e Venereologia do Centro Hospitalar de V. N. de- Eur J Dermatol. 2009 May-Jun;19(3):248-51. Epub 2009 Mar 3. ([DOI Direct Link](#))
- [Erlotinib-induced dermatologic side-effects.](#)  
*Cetuximab, a new recombinant monoclonal antibody that inhibits the...*18th June, 2009  
- Int J Dermatol. 2009 Mar;48(3):326-8. ([DOI Direct Link](#))
- [Acute acne flare following isotretinoin administration: potential protective role of low starting dose.](#)

- Adverse events with anti-epidermal growth factor receptor therapy mainly...*16th June, 2009  
- Dermatology. 2009;218(2):178-80. Epub 2008 Dec 5. ([DOI Direct Link](#))
- [A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.](#)  
*Epidermal growth factor receptor inhibitors (EGFRIs) are new anticancer...*13th June, 2009  
Dermatopathology Section, Boston University School of Medicine, Boston,- J Cutan Pathol. 2009 Dec;36(12):1303-7. Epub 2009 Jun 9. ([DOI Direct Link](#))
  - [Severe acneiform eruption exacerbated by dantrolene sodium.](#)  
*The epidermal growth factor receptor (EGFR) inhibitor erlotinib was found...*15th April, 2009  
- Clin Exp Dermatol. 2009 Mar;34(2):248-9. ([DOI Direct Link](#))
  - [Rosaceiform eruption induced by erlotinib.](#)  
*Adverse events with anti-epidermal growth factor receptor therapy mainly...*14th April, 2009  
Department of Specialistic and Experimental Clinical Medicine, Division of- Dermatol Ther. 2008 Oct;21 Suppl 2:S43-5. ([DOI Direct Link](#))
  - [Malassezia folliculitis presented as acneiform eruption after cetuximab administration.](#)  
*Cetuximab, a new recombinant monoclonal antibody that inhibits the...*1st April, 2009  
Department of Internal Medicine, General Hospital of Sitia, Greece.- J Drugs Dermatol. 2009 Mar;8(3):274-5.
  - [Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.](#)  
*OBJECTIVES: Determine if cetuximab dose escalation to induce grade 2 rash...*27th March, 2009  
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA- Gynecol Oncol. 2009 Apr;113(1):21-7. Epub 2009 Jan 21. ([DOI Direct Link](#))
  - [Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.](#)  
*The epidermal growth factor receptor (EGFR) inhibitor class of agents have...*20th February, 2009  
Rush University Medical Center, Chicago, IL 60612, USA.- J Drugs Dermatol. 2008 Dec;7(12):1161-3.

## BioNews Results for Acneiform Eruptions

- [Predictive Factors of Eczema-Like Eruptions among Patients without Cutaneous Psoriasis Receiving Infliximab: A Cohort Study of 92 Patients](#)  
*MDLinx: Oct 26 2009 11:35AM Matching: eruptions*

## Acneiform Eruptions Clinical Trials:



- [A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels.](#)



## Acneiform Eruptions Patents:

- 7615657- [Method of producing an oil extract from seeds of plants via a binary azeotropic solvent mixture](#)
- 5260292- [Topical treatment of acne with aminopenicillins](#)
- 5409917- [Topical treatment of acne with cephalosporins](#)
- 5505949- [Topical treatment for acne](#)
- 5594030- [Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid](#)
- 5837270- [Topical anti-acne composition](#)
- 6399651- [Method of treating dermatoses using avermectin compound](#)
- 6451773- [Chitosan formulation with azelaic acid and other actives for the treatment of acne](#)
- 6624199- [Aminobenzophenones](#)
- 6693077- [Keratinocyte growth factor-2](#)
- 7232667- [Keratinocyte growth factor-2 polynucleotides](#)
- 7359748- [Apparatus for total immersion photography](#)
- 7544674- [Topical skin care composition](#)
- 4946679- [Method for the treatment of premenstrual syndrome](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

